Natural History of Apparent Mineralocorticoid Excess Syndrome

Apparent Mineralocorticoid Excess Syndrome Clinical Trial

Official title:

Apparent Mineralocorticoid Excess Syndrome Natural History Clinical Protocol

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00474942
• Other study ID #: GCO 04-0474
• Secondary ID: U54HD064382RDCRN
• Status: Completed
• Phase: N/A
• First received: May 16, 2007
• Last updated: December 10, 2015
• Start date: April 2007
• Est. completion date: November 2013

Study information

• Verified date: December 2015
• Source: Icahn School of Medicine at Mount Sinai
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Federal Government
• Study type: Observational

Clinical Trial Summary

Apparent mineralocorticoid excess (AME) is a rare inherited disease that can cause severe high blood pressure and low blood potassium in children and adults. It is caused by abnormal hormone metabolism and can be fatal. This study will focus on the genetic basis, natural history, disease progression, and survival of people with AME.

Description:

AME is a rare genetic disorder that is caused by a mutated HSD11B2 gene, which encodes the metabolic enzyme 11BHSD2. The altered gene interferes with the ability of 11BHSD2 to inactivate the hormone cortisol. Above-normal cortisol activity then leads to a rise in blood pressure and a reduction of potassium in the blood. It also leads to low levels of the enzyme renin and the hormone aldosterone, both of which are involved in the regulation of long-term blood pressure. Long-term high blood pressure and metabolic defects start at an early age in children with severe AME. In others, AME may start later in life and cause less serious side effects. Symptoms can include poor growth in childhood, delayed puberty, muscle weakness, heart rate irregularity, frequent urination, and thirst. If left untreated, AME can cause serious damage to the eyes, kidneys, heart, and other organs.

Current treatment with the synthetic steroid spironolactone usually improves symptoms; however, despite treatment, some individuals with AME still experience disease progression and even death within years of being diagnosed with AME. Understanding more about AME, how it progresses, and how it affects people differently may help to improve treatment options. The purpose of this study is to examine the genetic basis, natural history, disease progression, and outcome of children and adults with AME. The study will also examine the family members of study participants with AME for any genetic abnormalities and possible mild forms of AME.

This study will last 2 to 7 years. Participants and their family members will attend yearly study visits that will include interviews about medical history, symptoms, and hospital stays; a physical exam; blood pressure testing; and blood and urine collection. Interim reviews of medical records will occur as necessary. Children will undergo an x-ray of the left hand. During the initial study visit, participants will be asked questions about family members and birth size.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 130
• Est. completion date: November 2013
• Est. primary completion date: November 2013
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: N/A and older

Eligibility

Inclusion Criteria for Participants with AME:

• High blood pressure characterized by low plasma renin and serum aldosterone levels

• Elevated urinary cortisol/cortisone metabolite ratio ([THF + 5aTHF]/THE)

• Molecular genetic diagnosis of AME with two mutations of the HSD11B2 gene

Inclusion Criteria for Family Members without Genetic Diagnosis of AME:

• Carrier of the HSD11B2 mutation that the AME participant has

Exclusion Criteria for All Participants:

• Any other illness or condition that might interfere with study participation

Study Design

Observational Model: Cohort, Time Perspective: Prospective

Related Conditions & MeSH terms

• Apparent Mineralocorticoid Excess Syndrome
• Hyperaldosteronism
• Syndrome

Locations

Country	Name	City	State
Brazil	University of Sao Paulo	Sao Paulo
France	University of Lyon	Lyon
United States	University of Texas Southwestern Medical Center	Dallas	Texas
United States	Mount Sinai School of Medicine	New York	New York

Sponsors (4)

Lead Sponsor	Collaborator
Icahn School of Medicine at Mount Sinai	Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), Office of Rare Diseases (ORD), Rare Diseases Clinical Research Network

Countries where clinical trial is conducted

United States,  Brazil,  France, 

References & Publications (3)

New MI, Geller DS, Fallo F, Wilson RC. Monogenic low renin hypertension. Trends Endocrinol Metab. 2005 Apr;16(3):92-7. Review. — View Citation

Palermo M, Quinkler M, Stewart PM. Apparent mineralocorticoid excess syndrome: an overview. Arq Bras Endocrinol Metabol. 2004 Oct;48(5):687-96. Epub 2005 Mar 7. Review. — View Citation

Quinkler M, Bappal B, Draper N, Atterbury AJ, Lavery GG, Walker EA, DeSilva V, Taylor NF, Hala S, Rajendra N, Stewart PM. Molecular basis for the apparent mineralocorticoid excess syndrome in the Oman population. Mol Cell Endocrinol. 2004 Mar 31;217(1-2):143-9. — View Citation